Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Systematic Review Article

Liraglutide for the Treatment of Obesity: Analyzing Published Reviews

Author(s): Rosario Pastor and Josep A. Tur*

Volume 25 , Issue 15 , 2019

Page: [1783 - 1790] Pages: 8

DOI: 10.2174/1381612825666190701155737

Price: $65


Background: Several drugs have been currently approved for the treatment of obesity. The pharmacokinetic of liraglutide, as well as the treatment of type 2 diabetes mellitus, have been widely described.

Objective: To analyze the published systematic reviews on the use of liraglutide for the treatment of obesity.

Methods: Systematic reviews were found out through MEDLINE searches, through EBSCO host and the Cochrane Library based on the following terms: "liraglutide" as major term and using the following Medical Subject Headings (MesH) terms: "obesity", "overweight", "weight loss". A total of 3 systematic reviews were finally included to be analyzed.

Results: From the three systematic reviews selected, only two included the randomized clinical trials, while the third study reviewed both randomized and non-randomized clinical trials. Only one review performed statistical tests of heterogeneity and a meta-analysis, combining the results of individual studies. Another review showed the results of individual studies with odds ratio and confidence interval, but a second one just showed the means and confidence intervals. In all studies, weight loss was registered in persons treated with liraglutide in a dose dependent form, reaching a plateau at 3.0 mg dose, which was reached just in men. Most usual adverse events were gastrointestinal.

Conclusion: More powerful and prospective studies are needed to assess all aspects related to liraglutide in the overweight and obesity treatment.

Keywords: Liraglutide, glucagon-like peptide-1 receptor agonist (GLP-1), obesity, overweight, weight loss, type 2 diabetes mellitus.

Martín J, Martín A. Epidemiología de la obesidad Análisis de determinantes dietéticos y de actividad físicaObesidad en el siglo XXI: ¿Qué se puede y qué se debe hacer?. Madrid: IMC 2009; pp. 27-33.
González Jiménez E. [Body composition: Assessment and clinical value]. Endocrinol Nutr 2013; 60(2): 69-75. [PMID: 22704270].
Rubio M, Salas-Salvadó J, Barbany M, et al. Consenso de la Sociedad Española para el Estudio de la Obesidad (SEEDO) 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Rev Esp Obes 2007; 128(5): 7-48.
Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes 2008; 32(Suppl. 3): S56-9. []. [PMID: 18695655].
Pasanisi F, Contaldo F, de Simone G, Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001; 11(6): 401-6. [PMID: 12055705].
Roberts CA, Christiansen P, Halford JCG. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? Acta Diabetol 2017; 54(8): 715-25. []. [PMID: 28421338].
Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig 2016; 7(Suppl. 1): 64-9. []. [PMID: 27186358].
Nuffer WA, Trujillo JM. Liraglutide: A new option for the treatment of obesity. Pharmacotherapy 2015; 35(10): 926-34. []. [PMID: 26497479].
Scott LJ. Liraglutide: A review of its use in the management of obesity. Drugs 2015; 75(8): 899-910. []. [PMID: 25985864].
Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet 2016; 293(3): 509-15. []. [PMID: 26660657].
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 2013; 37(11): 1443-51. []. [PMID: 23812094].
O’Neil PM, Garvey WT, González-Campoy JM, et al. Effects of Liraglutide 3.0 mg on weight and risk factors in Hispanic versus non-Hispanic populations: Subgroup analysis from scale randomized trials. Endocr Pract 2016; 22(11): 1277-87. []. [PMID: 27482610].
Bays H, Pi-Sunyer X, Hemmingsson JU, Claudius B, Jensen CB, Van Gaal L. Liraglutide 3.0 mg for weight management: Weight-loss dependent and independent effects. Curr Med Res Opin 2017; 33(2): 225-9. []. [PMID: 27817208].
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of Liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: Secondary analyses of pooled data from the SCALE Clinical Development Program. Diabetes Care 2017; 40(7): 839-48. []. [PMID: 28473337].
O’Neil PM, Aroda VR, Astrup A, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017; 19(11): 1529-36. []. [PMID: 28386912].
Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab 2018; 20(3): 734-9. []. [PMID: 28950422].
Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes 2016; 6(4): 233-42. []. [PMID: 27198973].
Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016; 24(11): 2278-88. []. [PMID: 27804269].
Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab 2016; 18(5): 491-9. []. [PMID: 26833744].
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373(1): 11-22. []. [PMID: 26132939].
Ard J, Cannon A, Lewis CE, et al. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes Metab 2016; 18(4): 430-5. []. [PMID: 26744025].
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial. Lancet 2017; 389(10077): 1399-409. []. [PMID: 28237263].
von Scholten BJ, Davies MJ, Persson F, et al. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. J Diabetes Complications 2017; 31(7): 1164-8. []. [PMID: 28462892].
le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X. Comparison of efficacy and safety of liraglutide 3.0 mg in individuals with BMI above and below 35 kg/m2: A post-hoc analysis. Obes Facts 2017; 10(6): 531-44. []. [PMID: 29145215].
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314(7): 687-99. []. [PMID: 26284720].

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy